Biocept Akcija

Biocept EBITDA

Delisted

Vrijednost EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Biocept (BIOC) na dan 4. авг 2026. je -31,98 М USD. Prethodne godine, EBITDA (Заработак пре камата, пореза, амортизације и отписивања) je bio -2,41 М USD — promjena od 1.227,65% (niži).

EBITDA

-31,98 МUSD

YoY

1.227,65%

Zadnja ažuriranja:

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Biocept je 2026 -31,98 М USD. EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Biocept je bio 2025 -2,41 М USD. Pad je time 1.227,65% niži u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

Biocept Анализа акција

Šta radi Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Biocept

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) kompanije Biocept iznosi -31,98 М USD u 2026. godini.

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Biocept se promijenio sa -2,41 М USD na -31,98 М USD, što predstavlja promjenu od 1.227,65%. Vrijednost je niži nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EBITDA (Заработак пре камата, пореза, амортизације и отписивања) Biocept od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

EBITDA мери оперативну перформансу пре утицаја финансијске структуре, окружења пореза и не-готовинских отписивања.

EBITDA = EBIT + Амортизација и отписивање

EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s USD je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s Biocept istorijski i u realnom vremenu.

Access this data via the Eulerpool API

Извештај о добити и губитку — Biocept

Sve ključne metrike — Biocept

Раст